Advertisement

Pharmacy

Home Pharmacy

The American College of Rheumatology, Nov. 3-8

The 81st Annual Meeting of the American College of Rheumatology The annual meeting of the American College of Rheumatology was held...
When adjuvant endocrine therapy for estrogen receptor-positive breast cancer is stopped after five years

Breast Cancer Recurrences Steady After Therapy Cessation

Women with ER-positive BC who stop therapy after 5 years have steady recurrence rate up to 20 years
For patients with inflammatory bowel disease

Lymphoma Risk Up With Thiopurine, Anti-TNF Tx in IBD

Risk higher for those exposed to combination therapy versus thiopurine or anti-TNF monotherapy
For patients presenting to the emergency department with acute extremity pain

In ER, Combination of Ibuprofen, Acetaminophen Relieves Pain

No difference in pain reduction for ibuprofen and acetaminophen vs. 3 opioid/acetaminophen combos
Factors including increases in health care service price and intensity are associated with increases in U.S. health care spending from 1996 to 2013

Increases in U.S. Health Spending Tied to Health Service Price

Higher spending also linked to population growth and aging, negatively linked to disease incidence
There has been little change in the treatment recommendations for cough due to the common cold since publication of guidelines in 2006

Evidence Scant for Treatment of Cough With the Common Cold

Update recommends against nonsteroidal anti-inflammatory agents for adults, codeine for children
For patients with Parkinson's disease and excessive daytime sleepiness

Sodium Oxybate Promising for Parkinson’s, Daytime Sleepiness

Improvements in subjective sleep quality, objectively measured slow-wave sleep duration
Differences in glycosylation between H3N2 egg-adapted vaccines and circulating strains probably reduced vaccine effectiveness during the 2016-2017 influenza season

Glycosylation Differences in Egg-Adapted Vaccines May Cut Impact

H3N2 egg-adapted vaccines, circulating strains were different in 2016-2017 influenza season
For patients with acute severe bleeding

Delay in Tranexamic Acid Administration Reduces Benefit

Survival benefit decreases by 10 percent for every 15-minute delay in treatment for severe bleeding
Zelboraf (vemurafenib) has been approved by the U.S. Food and Drug Administration as the first drug to treat certain adults patients with Erdheim-Chester disease.

Zelboraf Approved for Use in Erdheim-Chester Disease

Kinase inhibitor (vemurafenib) for use in patients with BRAF V600 mutation